REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/08/2025
Back to search
Official data from USPTO
MOLECULARHEALTH
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
MOLECULARHEALTH
ST13
US500000085583366Class
42, 44
Filing
85583366
Registration
4975047
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
72
Latest update
06/09/2025
Trademark type
Word
Nice classes
42, 44
Filing date
03/29/2012
Registration date
06/07/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/07/2023
Last transaction
06/09/2025
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Supplemental Register
Filing basis
Intent to use, Foreign priority
Drawing code
4
Owner type
16
Owner location
HEIDELBERG, DE
Examiner
DAHLING,KRISTIN M
Law office
L50
Current location
TMEG LAW OFFICE 105
Holders and representatives
Holders
MOLECULAR HEALTH GMBH
Molecular Health AG
Representatives
Robert S. Weisbein Foley & Lardner LLP
Technical classification
Nice Classes
Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Data collection for medical and scientific research purposesthe collection and systematic sorting of clinical and patient data comprising patient-specific molecular and genomic datapatient specific clinical data and scientific clinical studies; data collection for medical and scientific research purposesthe collection of mathematic and statistical dataclinical datapatient data and data of clinical studies relating to clinical response to drug treatments; providing medical and scientific research information and scientific consulting in the fields of pharmaceutical side effectsgenomicsbiological medicine and translational medicine; providing an online database comprised of medicalpharmaceuticalbiological and genomic information for scientific research purposes; providing an online searchable database in the fields of biological medicaltranslational medicineinterventional epidemiologybioinformaticsclinical information technologygenomic data and genomic sequence analysis for scientific research purposes; design and development of computer software in the fields of biologymedicinebioinformatics; design and development of computer software for integration of patient specific datamolecular test resultsclinical studies and scientific results; providing online non-downloadable computer software for use by healthcare professionals for medical treatment research; design and development of databases featuring biomarker data; providing an online searchable database for clinical and scientific research in the field of medicaldiagnostic and treatment research; Software as a Service (SAAS) services featuring software for providing information for patient treatment by enabling the retrieval and correlation of genomic datadrug protocolsclinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic datadrug protocolsclinical profiling and integration and statistical analysis of data for medical diagnostic and treatment research purposes; medical research and scientific research and scientific consulting servicesdesigning and conducting drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others; consulting services in the field of pharmaceuticals and geneticsconducting drug safety and dosage assessment and in drug compatibility studies in the field of cancer treatment therapy for others relating to diagnosticprophylactic and therapeutic properties of pharmaceuticals; Providing online non-downloadable computer software for use by healthcare professionals for medical diagnostics
Class 44
Providing an online database featuring medical information and diagnosticprophylactic and therapeutic properties of pharmaceuticalsgenomic information as it relates to medical diagnosis and treatment; pharmaceutical consulting services in pharmaceuticals and genetics in relation to patient medical treatment options; medical consulting services with respect to the treatment and diagnosis of individuals in the fields of clinical pharmacology and the analysis of dose effect relationships for treatment purposes; providing pharmaceutical informationinformation about drug safety and drug compatibility in relation to cancer therapy and the treatment of individual patients; medical consulting services in the fields of patient treatment and treatment protocols
Publications
History of USPTO decisions and trademark events.
72 publications found
NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/07/2023
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
06/07/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/05/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
12/17/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
12/17/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/17/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/17/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
12/17/2022
ES8R
TEAS SECTION 8 RECEIVED
12/06/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/07/2021
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
06/07/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
05/05/2016
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
04/28/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
04/27/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/27/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
04/27/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/27/2016
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/26/2016
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
03/29/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
03/11/2016
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
03/08/2016
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/04/2016
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/03/2016
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/03/2016
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/21/2015
GNRT
NON-FINAL ACTION E-MAILED
12/21/2015
CNRT
NON-FINAL ACTION WRITTEN
12/21/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/09/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/09/2015
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/30/2015
DOCK
ASSIGNED TO EXAMINER
10/19/2015
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
05/31/2015
GNRT
NON-FINAL ACTION E-MAILED
05/31/2015
CNRT
NON-FINAL ACTION WRITTEN
05/31/2015
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/06/2015
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/06/2015
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
04/28/2015
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/29/2014
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/29/2014
CNSI
SUSPENSION INQUIRY WRITTEN
10/29/2014
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/07/2014
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/20/2014
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
04/07/2014
GNSL
LETTER OF SUSPENSION E-MAILED
04/07/2014
CNSL
SUSPENSION LETTER WRITTEN
04/07/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/20/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/20/2014
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
03/14/2014
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
10/04/2013
GNSI
INQUIRY TO SUSPENSION E-MAILED
10/04/2013
CNSI
SUSPENSION INQUIRY WRITTEN
10/04/2013
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
09/19/2013
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
03/18/2013
GNSL
LETTER OF SUSPENSION E-MAILED
03/18/2013
CNSL
SUSPENSION LETTER WRITTEN
03/18/2013
XAEC
EXAMINER'S AMENDMENT ENTERED
03/07/2013
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/07/2013
GNEA
EXAMINERS AMENDMENT E-MAILED
03/07/2013
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/07/2013
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
01/31/2013
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/31/2013
ALIE
ASSIGNED TO LIE
01/24/2013
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
01/22/2013
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/22/2013
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/22/2012
GNRT
NON-FINAL ACTION E-MAILED
07/22/2012
CNRT
NON-FINAL ACTION WRITTEN
07/22/2012
DOCK
ASSIGNED TO EXAMINER
07/10/2012
MPMK
NOTICE OF PSEUDO MARK MAILED
04/05/2012
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/04/2012
NWAP
NEW APPLICATION ENTERED
04/02/2012
Continuous trademark protection
Get notified about every new filing that threatens MOLECULARHEALTH or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.